On the stock market since 2010, it operates in the world of health and science. It has 1,677 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 21% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $14.3M would still be left in the vault — a solid cushion for hard times.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 21% a year on average.
There is $30.6M in the vault; even if every debt were paid off, $14.3M would remain.
It pays out $0.84 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.0002. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, CNBI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CNBI is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.